Pamidronate Benefits Limited in Children With Osteogenesis Imperfecta

Description: NEW YORK (Reuters Health) Mar 08 - In children with osteogenesis imperfect, the value of pamidronate therapy appears to be restricted to the first few years of treatment, according to a report in the February issue of The Journal of Clinical Endocrinology & Metabolism. "Treatment with pamidronate (and likely with other bisphosphonates) is a double-edged sword," Dr. Frank Rauch from Shriners Hospital for Children and McGill University, Montreal, Quebec, Canada told Reuters Health. "The good thing is that it increases bone mass. But it also leads to suppression of bone turnover and accumulation of growth plate material in bone."